Latest

11.21.2022

Graybug and CalciMedica Enter into Definitive Merger Agreement

Read Article
08.09.2022

Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors

Read Article
08.02.2022

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis®

Read Article
06.02.2022

Cellworks Singula Therapy Response Index (TRI) Predicts Clinical Outcomes For Esophageal Adenocarcinoma: MyCare-004

Read Article
06.02.2022

Predictions of Overall Survival And Progression-Free Survival For Therapeutic Interventions In Glioblastoma Multiforme

Read Article
04.14.2022

Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer

Read Article
04.13.2022

OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

Read Article
12.23.2021

FDA Authorizes Merck’s Covid-19 Pill for At-Home Treatment

Read Article
Up NextAbout Us